論文

査読有り
2018年1月1日

Late relapse after a sustained virologic response at 24 weeks after treatment with daclatasvir and asunaprevir combination therapy for chronic hepatitis c virus genotype 1b infection with liver cirrhosis

Internal Medicine
  • Haruki Uojima
  • ,
  • Shuko Murakami
  • ,
  • Seigo Nakatani
  • ,
  • Hisashi Hidaka
  • ,
  • Atsuko Takeuchi
  • ,
  • Yoshiaki Tanaka
  • ,
  • Tomoyoshi Inoue
  • ,
  • Keiko Yamane
  • ,
  • Kousuke Kubota
  • ,
  • Takahide Nakazawa
  • ,
  • Akitaka Shibuya
  • ,
  • Yasuhito Tanaka
  • ,
  • Wasaburo Koizumi

57
7
開始ページ
951
終了ページ
956
DOI
10.2169/internalmedicine.9671-17

© 2018 The Japanese Society of Internal Medicine. There have been few studies on relapse after a sustained virological response in hepatitis C virus (HCV) patients treated with interferon-free regimens. Thus, the risk of late relapse in patients treated with interferon-free therapy remains unclear. A 67-year-old woman with HCV genotype 1b and liver cirrhosis received oral daclatasvir and asunaprevir. Combination therapy was stopped after 4 weeks because of an episode of encephalopathy. Nonetheless, an HCV polymerase chain reaction at 24 weeks posttreatment was negative. However, HCV ribonucleic acid was detectable at approximately 62 weeks posttreatment. Very late HCV relapses may occur in patients with liver cirrhosis who receive an interferon-free regimen when the treatment period is insufficient.

リンク情報
DOI
https://doi.org/10.2169/internalmedicine.9671-17
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29225269
Scopus
https://www.scopus.com/record/display.uri?eid=2-s2.0-85044711569&origin=inward
URL
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044711569&origin=inward